“…Because polyamine analogues do not substitute for the natural polyamines in growth accelerating function, they exhibit selective anticancer cytotoxicity. , Even minor structural changes in the polyamine analogue is sufficient to differentiate analogue with regard to its activity and toxicity in cancerous cells . The most successful analogues synthesized were the bis(ethyl) polyamines. , The analogue DENSpm, (N 1 ,N 11 di(ethyl)norspermine) is being used in clinical trials for hepatoma and is also being considered for combination trials. , CHENSpm ( N 1 -cycloheptylmethyl- N 11 -ethylnorspermine) has been reported to induce G2/M cell-cycle blockade in association with altered tubulin polymerization, but no clinical trials have been performed so far. , There are several recent studies on the interaction of polyamine analogues 333, BE-333, BE-3333, etc. with different forms of DNA and tRNA. ,, Many times, analogues are also assessed in combination with other anticancer drugs.…”